115 results
Page 3 of 6
8-K
EX-99.1
ll7mtmmy0wao z2nv
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
8-K
EX-99.1
tr0wwbplxx
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
EX-99.1
uwfp744
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
8-K
EX-99.1
bh92lbn 1tvy87
8 Nov 22
Completion of Acquisition or Disposition of Assets
8:40am
8-K
EX-99.1
91rwkd6t8sc da8kvno
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-4.3
miq0rtg4g x27cj8m
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
xv1hz
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-99.2
6lu5 ay40
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
424B4
a2bxn8xthns07l6
11 Oct 22
Prospectus supplement with pricing info
8:27am
FWP
6n6fe6
6 Oct 22
Free writing prospectus
4:05pm
8-K
EX-99.1
14lehc55rtum ajbgpqu
22 Sep 22
Material Modifications to Rights of Security Holders
4:32pm